AU2010252447B2 - Preparation methods and uses of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)-pyridone compounds and their salts - Google Patents

Preparation methods and uses of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)-pyridone compounds and their salts Download PDF

Info

Publication number
AU2010252447B2
AU2010252447B2 AU2010252447A AU2010252447A AU2010252447B2 AU 2010252447 B2 AU2010252447 B2 AU 2010252447B2 AU 2010252447 A AU2010252447 A AU 2010252447A AU 2010252447 A AU2010252447 A AU 2010252447A AU 2010252447 B2 AU2010252447 B2 AU 2010252447B2
Authority
AU
Australia
Prior art keywords
trifluoromethyl
compound
pyridin
amino
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010252447A
Other languages
English (en)
Other versions
AU2010252447A1 (en
Inventor
Jun Chen
Gaoyun Hu
Lijian Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Central South University
Original Assignee
Central South University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central South University filed Critical Central South University
Publication of AU2010252447A1 publication Critical patent/AU2010252447A1/en
Application granted granted Critical
Publication of AU2010252447B2 publication Critical patent/AU2010252447B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2010252447A 2009-05-25 2010-05-24 Preparation methods and uses of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)-pyridone compounds and their salts Ceased AU2010252447B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910043501 2009-05-25
CN200910043501.7 2009-05-25
PCT/CN2010/073105 WO2010135972A1 (zh) 2009-05-25 2010-05-24 1-(取代芳基)-5-三氟甲基-2-（1h）吡啶酮化合物及其盐的制备方法及其用途

Publications (2)

Publication Number Publication Date
AU2010252447A1 AU2010252447A1 (en) 2011-12-15
AU2010252447B2 true AU2010252447B2 (en) 2014-08-28

Family

ID=43222160

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010252447A Ceased AU2010252447B2 (en) 2009-05-25 2010-05-24 Preparation methods and uses of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)-pyridone compounds and their salts

Country Status (7)

Country Link
US (1) US8426407B2 (enExample)
EP (1) EP2436670B1 (enExample)
JP (1) JP5583758B2 (enExample)
KR (1) KR101522924B1 (enExample)
CN (1) CN102149682B (enExample)
AU (1) AU2010252447B2 (enExample)
WO (1) WO2010135972A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
CN102786467A (zh) * 2012-08-15 2012-11-21 浙江省医学科学院 一种n-取代芳基吡啶酮化合物及其制备方法和应用
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP6454348B2 (ja) 2013-12-19 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 窒素複素環誘導体およびその医薬品への応用
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
WO2015171345A1 (en) * 2014-04-30 2015-11-12 Auspex Pharmaceuticals, Inc. N-aryl pyridinones modulators of fibrosis and/or collagen infiltration
CN106466318B (zh) * 2015-08-21 2019-01-01 中南大学 1-杂环取代苄基吡啶酮类化合物在制备治疗糖尿病肾病药物中的应用
CN113476447A (zh) * 2021-07-09 2021-10-08 中南大学 一种美氟尼酮在制备急性肝损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101235030A (zh) * 2007-01-30 2008-08-06 中南大学 1-取代-5-三氟甲基-2-(1h)吡啶酮化合物、制备方法及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
GB8523126D0 (en) 1985-09-19 1985-10-23 Ici Plc Aryl pyridones
GB8621217D0 (en) 1986-09-03 1986-10-08 Ici Plc Chemical compounds
GB8825314D0 (en) 1988-10-28 1988-11-30 Ici Plc Chemical compounds
GB9006479D0 (en) 1989-04-17 1990-05-23 Ici Plc Novel compounds
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5238906A (en) 1990-11-27 1993-08-24 Sumitomo Chemical Company, Limited Pyridone derivatives and use
DE4343528A1 (de) 1993-12-16 1995-06-22 Schering Ag Zweifach heterocyclisch substituierte Benzole und Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
AP1822A (en) 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
CN1218942C (zh) * 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
US7825133B2 (en) * 2003-11-14 2010-11-02 Shanghai Genomics, Inc. Derivatives of pyridone and the use of them
DE102004027359A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
ZA200709593B (en) 2005-05-10 2009-06-24 Intermune Inc Pyridone derivatives for modulating stress-activated protein kinase system
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
US20110034495A1 (en) 2005-11-23 2011-02-10 Intermune, Inc. Method of Modulating Stress-Activated Protein Kinase System
US20090118135A1 (en) 2007-06-08 2009-05-07 The Burnham Institute Methods and compounds for regulating apoptosis
CN101371833A (zh) 2007-08-23 2009-02-25 中南大学 1-芳基-2(1h)-吡啶酮类化合物在制备治疗皮肤瘙痒药物中的应用
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
EP2389227A4 (en) 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
WO2010135470A1 (en) 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101235030A (zh) * 2007-01-30 2008-08-06 中南大学 1-取代-5-三氟甲基-2-(1h)吡啶酮化合物、制备方法及其用途

Also Published As

Publication number Publication date
CN102149682B (zh) 2012-12-05
EP2436670A4 (en) 2012-11-21
KR101522924B1 (ko) 2015-05-26
KR20120025541A (ko) 2012-03-15
JP2012527487A (ja) 2012-11-08
AU2010252447A1 (en) 2011-12-15
JP5583758B2 (ja) 2014-09-03
WO2010135972A1 (zh) 2010-12-02
EP2436670B1 (en) 2014-04-16
US8426407B2 (en) 2013-04-23
HK1164297A1 (en) 2012-10-12
EP2436670A1 (en) 2012-04-04
US20120142688A1 (en) 2012-06-07
CN102149682A (zh) 2011-08-10

Similar Documents

Publication Publication Date Title
AU2010252451B2 (en) 1-(substituted benzyl)-5-trifluoromethyl-2-(1H) pyridone compounds and their salts, their preparation methods and use thereof
EP2436670B1 (en) Preparation of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)pyridone compounds and salts thereof and their applications
JP2023071905A (ja) 癌を処置するためのｅｚｈ２阻害剤
TW502019B (en) Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
CN105384739B (zh) 吡唑并[3,4-c]吡啶类衍生物
CA3184062A1 (en) Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
EA020976B1 (ru) Фторированные производные 3-гидроксипиридин-4-онов и способы их использования
CN113045498A (zh) 一种1,5-二芳基吡唑衍生物、合成方法及用途
HK1164297B (en) Preparation of 1-(substituted aryl)-5-trifluoromethyl-2-(1h)-pyridone compounds and salts thereof and their applications
US20240025845A1 (en) Metastasis-inhibiting composition of novel methylsulfonamide derivative compound
HK1166791B (en) Preparation of 1-(substituted benzyl)-5-trifluoromethyl-2-(1h)pyridone compounds and salts thereof and their applications
KR102623917B1 (ko) 암 세포의 이동과 침윤 억제를 통한 암 전이 억제제
CN121248496B (zh) 邻氨基吡啶甲酰腙类化合物及其制备方法和用途
KR101958107B1 (ko) 신규 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 또는 치료용 약학적 조성물
HK40113709A (en) Therapeutic combinations comprising ubiquitin specific-processing protease 1 (usp1) inhibitors and chemotherapy agents
TW202602447A (zh) 用於傷口治療之wnt途徑抑制劑之醫藥組合物
CN122070291A (zh) 生理功能和稳态调控化合物和其用途
WO2014196784A1 (ko) 신규한 말레인산 유도체 및 이의 제조방법 및 이를 포함하는 항암용 조성물
WO2022243573A1 (en) 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
CN104370843B (zh) 卤代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
WO2017216576A1 (en) Autophagy inducer compounds
JPWO2003097060A1 (ja) トロポロン誘導体を用いた経口投与用頻尿・尿失禁の治療剤又は予防剤若しくは経口投与用睡眠導入剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired